Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, July 28, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, July 27, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Andrew Berens Upgraded (AGIO) to Buy and Held Target at $33 on, Jul 27th, 2022
Andrew Berens of SVB Leerink, Upgraded "Agios Pharmaceuticals, Inc." (AGIO) to Buy and Held Target at $33 on, Jul 27th, 2022.
Andrew has made no other calls on AGIO in the last 4 months.
There is 1 other peer that has a rating on AGIO. Out of the 1 peers that are also analyzing AGIO, 0 agree with Andrew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Andrew
- Salveen Richter of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $16 on, Tuesday, May 24th, 2022
